Artículos del autor

solaci

Chronic Ischemic cardiopathy

Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM

In November 2019, during the American Heart Association (AHA) 2019 Scientific Sessions, researchers presented this revolutionary trial...
solaci -
Acute coronary syndromes

Virtual ACC 2020 | Colchicine After Infarction: Good Results and Cost-Effectiveness

Low doses of colchicine reduce the risk of ischemic events after an acute myocardial infarction, according to...
solaci -
Antiplatelet

Virtual ACC 2020 | TAILOR-PCI: Gene-Based Prescribing of Clopidogrel Does Not Change Outcomes

This very interesting work leaves us with a sour taste in our mouth, as it failed to...
solaci -
Other

Virtual ACC 2020 | Vericiguat: New Hope in Chronic Cardiac Failure

Treatment with the new drug called Vericiguat (acting on guanosine monophosphate receptors GMP) might reduce cardiovascular mortality...
solaci -
Antithrombotic Anticoagulants

Virtual ACC 2020 | VOYAGER PAD: Rivaroxaban Superior to Aspirin in Preventing Events

In patients with peripheral artery disease undergoing revascularization, the combination of rivaroxaban (Xarelto) and low doses of...
solaci -
Chronic Ischemic cardiopathy

Virtual ACC 2020 | More data from ISCHEMIA: Women with More Symptoms but Less Ischemia

The ISCHEMIA trial will keep shedding light. The latest data show important differences between men and women...
solaci -
Antithrombotic Anticoagulants

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses...
solaci -
Acute coronary syndromes

16 Years of Superiority of Primary Angioplasty

The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial showed the 30-day superiority of patient transport to a...
solaci -